OFD 2024 Bilingual (English / French)

Session Detail

Saturday
Nov 2 2024
Plenary session
Diagnostic Markers in Oncology - What Every Oncology Pharmacy Practitioner Should Know
Presenters
Marc Geirnaert
Photo of Marc Geirnaert
Photo of Marc Geirnaert
Marc Geirnaert
Director of Provincial Oncology Drug Program, Pharmacy, CancerCare Manitoba — Winnipeg, Manitoba
Marc Geirnaert graduated from the University of Manitoba with his Bachelor of Sciences in Pharmacy in 2002. Marc is a Board Certified Oncology Pharmacist (BCOP) and received his FCAPhO (Fellow of Canadian Association of Pharmacy in Oncology) designation in 2023. Marc started working in oncology and hematology in January 2003 and has worked in a variety of clinics such as lymphoproliferative diseases, genitourinary and central nervous system tumors. Since June 2014, Marc is the Director of Provincial Oncology Drug Program at CancerCare Manitoba. Marc is also the current chair of the pan Canadian Oncology Drug Review (pCODR) Provincial Advisory Group. Marc’s interests include implementation of new therapies in oncology/hematology including immunotherapies and biosimilars.
Marc Geirnaert
CancerCare Manitoba, Winnipeg, Manitoba

Presentation summary
This presentation will provide an essential overview of the most common diagnostic tests that are used in the treatment of solid tumors and blood cancers. The participants will understand why the tests are important for drug selection and why such tests are ordered.

Learning Objectives:
1. Identify the most common diagnostic tests used in hematological cancers and the significance of the test results.
2. Explain what is meant by dMMR, MSI-H, pMMR, MSI-L and MSS.
3. List the most common diagnostic tests for breast cancer.
4. Understand the most common diagnostic tests for lung cancer.